![PDF) Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis PDF) Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis](https://i1.rgstatic.net/publication/341599471_Best_Practice_Approach_to_Successful_Conversion_of_Fosaprepitant_to_Aprepitant_IV_in_a_Large_Multisite_Community_Oncology_Infusion_Center_A_Retrospective_Analysis/links/5ec95866299bf1c09ad631f2/largepreview.png)
PDF) Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis
Article: Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy (full text) - April 2018 - NJM
Openbaar Beoordelingsrapport - Samenvatting Generieke geneesmiddelen Aprepitant Teva 80 mg, 125 mg, en 125 mg + 80 mg, harde cap
CHARAKTERYSTYKA PRODUKTU LECZNICZEGO 1. NAZWA PRODUKTU LECZNICZEGO Aprepitant Teva, 125 mg/80 mg, kapsułki, twarde 2. SKŁA
![Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States | Business Wire Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States | Business Wire](https://mms.businesswire.com/media/20210114006024/en/739014/23/teva_RGB_JPEG.jpg)